Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges

Rezaei, Sahar; Gharapapagh, Esmaeil; Dabiri, Shahram; Heidari, Pedram; Aghanejad, Ayuob

doi:10.1016/j.lfs.2023.121970

Cited by 6 publications

(4 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) has revolutionized the field of tumor imaging, its specificity and sensitivity are limited in certain tumor subtypes ( Chandekar et al, 2023 ). Fibroblast activation protein (FAP) is a type II integral membrane glycoprotein expressed by CAFs and has been identified as a crucial biomarker for CAFs ( Rezaei et al, 2023 ). Importantly, FAP is involved in various pathological processes and is selectively overexpressed in majority of tumors (over 90% of malignant epithelial tumors), making it a potential pan-cancer target ( Chen and Song, 2019 ; Fitzgerald and Weiner, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Mapping knowledge structure and themes trends of cancer-associated fibroblasts: a text-mining study

Cheng,

Li,

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: Cancer-associated fibroblasts (CAFs) constitute an important component of the tumor microenvironment, participating in various facets of cancer advancement and being recognized as contributors to tumor immune evasion. The role of CAFs in various tumor types has attracted increasing attention recently. In this work, we conducted a comprehensive bibliometric analysis to uncover research trajectories and highlight emerging areas in the field of CAFs.Methods: A systematic search was performed within the Web of Science Core Collection to identify articles/reviews on CAFs published between 2000 and 2023. Leveraging advanced bibliometric tools such as VOSviewer, CiteSpace, and online website, we examined and visualized publication trends, geographic contributions, institutional affiliations, journal prominence, author collaborations, and noteworthy references, keywords, and genes.Results: Our analysis included 5,190 publications, indicating a rapid growth trend in both annual publications and citations related to CAFs. China and the United States emerged as the foremost contributors in terms of publications, funding agencies, and international collaborations. Breast cancer was the most studied tumor, followed by colorectal cancer, pancreatic cancer, prostate cancer, and gastric cancer. Based on co-occurrence and bursting keywords, we identified the following research topics including immune cells (T cells, B-cells, tumor-associated macrophages), tumor immune microenvironment (antitumor immunity, immune infiltration, immunosuppression), immunotherapy (PD-L1), microRNAs (miRNA), extracellular vesicles (exosome), multiple tumors (pancreatic ductal adenocarcinoma, bladder cancer, head and neck squamous cell carcinoma), antitumor agents (gemcitabine, cisplatin resistance), bioinformatics (pan-cancer), epithelial-mesenchymal transition (stemness), FAPI PET/CT, DNA methylation, etc., may receive sustained attention in the future. Furthermore, TGFB1, IL-6, TNF, TP53, and VEGFA emerged as the top 5 genes that have garnered the greatest research attention in the field of CAFs. The KEGG enrichment analysis highlighted that the top 20 most studied genes were mainly associated with HIF-1 and Toll-like receptor signaling pathways.Discussion: In sum, our bibliometric analysis offers a comprehensive overview of the research landscape in the field of CAFs. It encompasses the current state, evolving patterns, and prospective avenues of exploration, with special attention to the potential advancements in tumor immune microenvironment.

show abstract

Section: Discussionmentioning

confidence: 99%

Mapping knowledge structure and themes trends of cancer-associated fibroblasts: a text-mining study

Cheng,

Li,

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…There are also some challenges in delivering CAR-T cells to solid tumors through molecular imaging and cell tracking is essential. This CAR-T cell therapy in treating both solid and non-solid tumors highlights current advances and discusses strategies for overcoming hurdles in treatment [ 70 ].…”

Section: Universal-influenza Vaccinesmentioning

confidence: 99%

Influenza vaccine: a review on current scenario and future prospects

Gupta,

Mohan

2023

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Vaccination is a crucial tool in preventing influenza, but it requires annual updates in vaccine composition due to the ever-changing nature of the flu virus. While healthcare and economic burdens have reduced, the virus remains a challenge. Research conducted over the past decade has revealed pathways for improvement through both basic and clinical studies. Viral surveillance plays a vital role in the better selection of candidate viruses for vaccines and the early detection of drug-resistant strains.This page offers a description of future vaccine developments and an overview of current vaccine options. In the coming years, we anticipate significant changes in vaccine production, moving away from traditional egg-based methods towards innovative technologies such as DNA and RNA vaccines. These newer approaches offer significant advantages over traditional egg-based and cell culture-based influenza vaccine manufacturing.

show abstract

“…Identification of specific biomarkers on the surface of CAFs offers a strategic avenue for targeted radiological diagnostics and therapeutics [ 59 , 60 , 61 , 62 , 63 , 64 ]. Among these biomarkers, fibroblast activation protein (FAP) has gained widespread attention for its potential in CAF identification and targeting [ 65 , 66 , 67 , 68 , 69 , 70 , 71 ]. FAP, a member of the dipeptidyl peptidase 4 (DPP4) family, boasts a molecular weight of 170 kDa [ 72 , 73 , 74 , 75 , 76 ].…”

Section: Introductionmentioning

confidence: 99%

Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals

Sun,

Wu,

Wang

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Fibroblast activation protein (FAP) is a serine protease characterized by its high expression in cancer-associated fibroblasts (CAFs) and near absence in adult normal tissues and benign lesions. This unique expression pattern positions FAP as a prospective biomarker for targeted tumor radiodiagnosis and therapy. The advent of FAP-based radiotheranostics is anticipated to revolutionize cancer management. Among various types of FAP ligands, peptides and antibodies have shown advantages over small molecules, exemplifying prolonged tumor retention in human volunteers. Within its scope, this review summarizes the recent research progress of the FAP radiopharmaceuticals based on antibodies and peptides in tumor imaging and therapy. Additionally, it incorporates insights from recent studies, providing valuable perspectives on the clinical utility of FAP-targeted radiopharmaceuticals.

show abstract

Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges

Cited by 6 publications

References 106 publications

Mapping knowledge structure and themes trends of cancer-associated fibroblasts: a text-mining study

Mapping knowledge structure and themes trends of cancer-associated fibroblasts: a text-mining study

Influenza vaccine: a review on current scenario and future prospects

Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals

Contact Info

Product

Resources

About